- Home
- PRAA vs MYGN Comparison
PRAA vs MYGN Comparison
Compare PRAA & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAA
- MYGN
- Stock Information
- Founded
- PRAA 1996
- MYGN 1991
- Country
- PRAA United States
- MYGN United States
- Employees
- PRAA N/A
- MYGN N/A
- Industry
- PRAA Finance: Consumer Services
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PRAA Finance
- MYGN Health Care
- Exchange
- PRAA Nasdaq
- MYGN Nasdaq
- Market Cap
- PRAA 620.1M
- MYGN 642.0M
- IPO Year
- PRAA N/A
- MYGN 1995
- Fundamental
- Price
- PRAA $13.89
- MYGN $7.69
- Analyst Decision
- PRAA Strong Buy
- MYGN Hold
- Analyst Count
- PRAA 3
- MYGN 13
- Target Price
- PRAA $26.00
- MYGN $13.50
- AVG Volume (30 Days)
- PRAA 318.5K
- MYGN 1.5M
- Earning Date
- PRAA 11-03-2025
- MYGN 11-06-2025
- Dividend Yield
- PRAA N/A
- MYGN N/A
- EPS Growth
- PRAA 2208.29
- MYGN N/A
- EPS
- PRAA 2.32
- MYGN N/A
- Revenue
- PRAA $1,132,016,000.00
- MYGN $832,900,000.00
- Revenue This Year
- PRAA $5.16
- MYGN $0.17
- Revenue Next Year
- PRAA $8.28
- MYGN $6.19
- P/E Ratio
- PRAA $6.15
- MYGN N/A
- Revenue Growth
- PRAA 15.79
- MYGN 3.83
- 52 Week Low
- PRAA $12.91
- MYGN $3.76
- 52 Week High
- PRAA $25.43
- MYGN $26.60
- Technical
- Relative Strength Index (RSI)
- PRAA 27.13
- MYGN 56.78
- Support Level
- PRAA $15.54
- MYGN $7.04
- Resistance Level
- PRAA $16.10
- MYGN $8.25
- Average True Range (ATR)
- PRAA 0.56
- MYGN 0.38
- MACD
- PRAA -0.35
- MYGN -0.05
- Stochastic Oscillator
- PRAA 0.70
- MYGN 51.04
About PRAA PRA Group Inc.
PRA Group Inc is a leader in acquiring and collecting nonperforming loans. The company returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe, and Australia. It is also engaged in providing fee-based services on class action claims recoveries in the United States. The company's portfolio segments include; Core, which is engaged in purchasing and collecting nonperforming loans, which the originators have not chosen not to pursue, and the Insolvency segment which is engaged in purchasing and collecting nonperforming loans where the customer is involved in a bankruptcy proceeding.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.